Caribou Biosciences, Inc.
General ticker "CRBU" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $177.0M (TTM average)
Caribou Biosciences, Inc. follows the US Stock Market performance with the rate: 13.9%.
Estimated limits based on current volatility of 3.0%: low 1.45$, high 1.54$
Factors to consider:
- Earnings expected soon, date: 2026-08-12 bmo
- Total employees count: 147 (-7.0%) as of 2024
- US accounted for 92.8% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Limited operating history, Clinical trial failure, Regulatory and compliance, Manufacturing supply issues, Commercialization challenges
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.27$, 3.30$]
- 2026-12-31 to 2027-12-31 estimated range: [1.19$, 3.12$]
Financial Metrics affecting the CRBU estimates:
- Positive: with PPE of -1.2 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -71.53 <= 0.30
- Positive: Investing cash flow per share per price, % of 65.89 > -0.65
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Shareholder equity ratio, % of 69.67 > 63.79
- Negative: negative Net income
Short-term CRBU quotes
Long-term CRBU plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $34.48MM | $9.99MM | $11.16MM |
| Operating Expenses | $150.54MM | $176.61MM | $159.50MM |
| Operating Income | $-116.06MM | $-166.62MM | $-148.34MM |
| Non-Operating Income | $14.18MM | $17.50MM | $-0.33MM |
| R&D Expense | $112.08MM | $130.15MM | $109.44MM |
| Income(Loss) | $-101.88MM | $-149.11MM | $-148.68MM |
| Taxes | $0.19MM | $-0.01MM | $-0.55MM |
| Net Income(Loss)* | $-102.07MM | $-149.10MM | $-148.12MM |
| Stockholders Equity | $368.40MM | $252.95MM | $122.17MM |
| Assets | $432.21MM | $313.31MM | $175.37MM |
| Operating Cash Flow | $-93.29MM | $-138.20MM | $-110.99MM |
| Capital expenditure | $11.61MM | $6.50MM | $1.36MM |
| Investing Cash Flow | $-68.18MM | $86.61MM | $102.24MM |
| Financing Cash Flow | $154.30MM | $16.72MM | $4.82MM |
| Earnings Per Share** | $-1.38 | $-1.65 | $-1.59 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.